Trial Profile

CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buprenorphine/naloxone (Primary) ; Naltrexone (Primary)
Indications Opioid-related disorders
Focus Therapeutic Use
Acronyms X:BOT

Most Recent Events

01 Mar 2025 Results of secondary analysis based on data from this study investigating the effects of buprenorphine versus naltrexone on cannabis use outcomes in treatment seeking individuals with Opioid Use Disorder published in the Drug and Alcohol Dependence.
01 Jul 2022 Results published in the Drug and Alcohol Dependence
18 Apr 2022 Results published in the Journal of Clinical Psychiatry

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com